Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeEXECUTIVESAlex C. Sapir Apppointed CEO of ReViral

Alex C. Sapir Apppointed CEO of ReViral

Alex C. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).The news was announced today. Sapir brings to ReViral many years of combined strategic and commercial experience in the biotechnology industry.

Alex C. Sapir has been appointed CEO of ReViral.  Mr. Sapir was also elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).The news was announced today.

“Today, ReViral has a rich pipeline of wholly-owned RSV antiviral product candidates and strong research,” said Dr. Kenneth Powell, Chairman of the Board. “Alex’s proven leadership skills combined with his deep experience building biotech businesses make him ideally suited to take ReViral to the next level. On behalf of the Board of Directors, I’d also like to thank Eddy for his successful time at ReViral as CEO, where we now see the Company’s lead product, sisunatovir (RV521), poised to enter international, pediatric Phase II clinical trials this year. His leadership has been instrumental to ReViral’s evolution, and we look forward to benefiting from his continued input and guidance as COO.”

Alex C. Sapir brings to ReViral many years of combined strategic and commercial experience in the biotechnology industry. From 2016 through 2018, Alex was the President and CEO at Dova Pharmaceuticals (NASDAQ: DOVA). During Alex’s tenure, the company raised $160M through a successful Initial Public Offering (IPO) and subsequent follow-on offering. With those proceeds Dova Pharmaceuticals grew from a small, private, pre-commercial company to a 150-person, fully-integrated, publicly-traded biotech company with an approved and marketed product and a rich pipeline of ongoing clinical programs.

From January 2006 to May 2016, Alex C. Sapir served as Executive Vice President for United Therapeutics Corporation, a biotechnology company focused on pulmonary arterial hypertension and pediatric oncology. During his 10-year tenure at United Therapeutics, Alex was responsible for all commercial-related activity, seeing the company grow from a one product company generating $80M in revenues to a five-product company generating $1.6B annually. Mr. Sapir began his pharmaceutical career at GlaxoSmithKline, where he served in a variety of strategic and commercial roles in both the United States and Europe. He received his B.A. in Economics from Franklin and Marshall College and his MBA from Harvard Business School. He, along with Seth Hetherington, ReViral’s recently appointed Chief Medical Officer, will be based in North Carolina’s Research Triangle Park in the United States.

“I am honored to assume this role at such an important time in the Company’s evolution, and I look forward to working with the Company’s leadership, employees, and Board of Directors to develop novel RSV therapies that hold the potential to deliver life-changing outcomes for patients around the world,” said Mr. Sapir. “The morbidity and mortality associated with RSV remains high given the lack of available treatment options. With sisunatovir poised to enter Phase II trials, coupled with a strong portfolio of earlier-stage RSV candidates led by a world-renowned team of scientists with a track record of developing antiviral drugs, ReViral is well positioned to become a leader in the RSV market.”

“It has been a privilege to serve as the CEO of ReViral during its evolution into a clinical stage company, and I am delighted to welcome Alex on board,” said Dr. Littler. “Alex’s experience running public biotech companies will enable ReViral to realize its full potential as it continues to discover and develop transformative RSV therapies for patients in need.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy